You searched for clinical trials - Page 37 of 44

ASH 2022: Dr. James Blachly Discusses Results from a Phase 1/2 Dose Escalation and Expansion Study Evaluating MS-533, a Novel and Selective Protein Kinase C-Beta Inhibitor in Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

February 15, 2023

MS-553, a protein kinase C-beta (PKCß) inhibitor, is an exciting new agent in a yet-to-be-approved class of drugs that target an area of the B-cell receptor pathway independent of Bruton tyrosine kinase (BTK) and phospholipase C gamma 2 (PLCy2) mutations which confer resistance to BTK inhibitors.

ASH 2022: Dr. Irina Murakhovskaya on Warm Autoimmune Hemolytic Anemia (wAIHA) in Patients with Chronic Lymphocytic Leukemia (CLL)

February 15, 2023

Warm autoimmune hemolytic anemia is a common and serious complication of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The ENERGY study will test the efficacy of nipocalimab for treating warm autoimmune hemolytic anemia.

CLL Society’s COVID-19 Update for the Week of January 30, 2023

January 30, 2023

Here is your weekly summary of what has been happening this past week of January 30, 2023 in the United States.

FDA Approves Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

January 30, 2023

On 1/27/23 Loxo@Lilly announced the Federal Drug Administration (FDA)’s accelerated approval of pirtobrutinib in adult patients with relapsed or refractory mantle cell lymphoma (MCL) following at least 2 lines of systemic therapy, including a BTK inhibitor.

FDA Announces Evusheld is Not Currently Authorized for Emergency Use in the U.S.

January 30, 2023

As of 1/26/23, Evusheld (tixagevimab co-packaged with cilgavimab) is no longer available as Pre-Exposure Prophylaxis (PrEP) in the United States. That decision was made because as the virus continued to mutate, now over 90% of SARS-CoV-2 variants of concerns (VOC) circulating in the U.S. are no longer believed to be neutralized by the monoclonal antibody (mAb) cocktail.

ASH 2022: Dr. Christine Ryan on Triple Combination Acalabrutinib, Venetoclax, and Obinutuzumab for High-Risk Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL / SLL)

January 6, 2023

In this ongoing trial, the triple combination therapy with acalabrutinib, venetoclax, and obinutuzumab is highly active and has thus far produced durable remissions as a frontline treatment in patients with TP53-aberrant chronic lymphocytic leukemia (CLL), which was generally well tolerated with a low 2.9% incidence of atrial fibrillation with none of the more serious abnormal ventricular heart irregularities seen.

MEI Pharma and Kyowa Kirin Announce Discontinuation of Zandelisib Development Outside of Japan Following Recent FDA Meeting

December 6, 2022

Zandelisib joins umbralisib in the parade of PI3K inhibitors that won’t be developed as an option for chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL / SLL) patients that have run out of options.

Obinutuzumab/Acalabrutinib/Venetoclax Combo Misses the Mark for MRD in Advanced Chronic Lymphocytic Leukemia (CLL)

November 18, 2022

The combination of obinutuzumab (Gazyva), acalabrutinib (Calquence), and venetoclax (Venclexta) failed to meet the pre-specified rate of undetectable measurable or minimal residual disease (uMRD) following optimal debulking with bendamustine in patients with relapsed/refractory chronic lymphocytic leukemia (CLL).

ASH 2021: Trial in Progress: Phase 1/2 Study Evaluating the Safety and Efficacy of IOV-2001, an Autologous, Non-Genetically Modified, Polyclonal T-Cell Product, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

September 22, 2022

Dr. Javier Pinilla Ibarz and colleagues presented this research at the American Society for Hematology annual meeting, which was held in December 2021 (ASH 2021).

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Search Results for: clinical trials – Page 37

ASH 2022: Dr. James Blachly Discusses Results from a Phase 1/2 Dose Escalation and Expansion Study Evaluating MS-533, a Novel and Selective Protein Kinase C-Beta Inhibitor in Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

ASH 2022: Dr. Irina Murakhovskaya on Warm Autoimmune Hemolytic Anemia (wAIHA) in Patients with Chronic Lymphocytic Leukemia (CLL)

CLL Society’s COVID-19 Update for the Week of January 30, 2023

FDA Approves Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

FDA Announces Evusheld is Not Currently Authorized for Emergency Use in the U.S.

ASH 2022: Dr. Christine Ryan on Triple Combination Acalabrutinib, Venetoclax, and Obinutuzumab for High-Risk Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL / SLL)

MEI Pharma and Kyowa Kirin Announce Discontinuation of Zandelisib Development Outside of Japan Following Recent FDA Meeting

Obinutuzumab/Acalabrutinib/Venetoclax Combo Misses the Mark for MRD in Advanced Chronic Lymphocytic Leukemia (CLL)

ASH 2021: Trial in Progress: Phase 1/2 Study Evaluating the Safety and Efficacy of IOV-2001, an Autologous, Non-Genetically Modified, Polyclonal T-Cell Product, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Didn't find what you where looking for?

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT CLL SOCIETY

CONTACT